Neurons die following certain brief seizures. Such neuronal death may contribute to cognitive decline in patients with poorly managed seizures, or contribute to more severe seizures in epileptic brain. Brief seizures activate a coordinated molecular pathway within the hippocampus that involves dimerization interactions of pro- and antiapoptotic members of the Bcl-2 gene family and their satellite regulators, protein kinase B and 14-3-3 proteins. Pharmacological interventions confirm this pathway drives as much as half of cell death after seizures. Our preliminary data reveals that expression and interaction of two cell death regulators, Bcl-w and Bim, are fundamentally critical to whether seizures cause neuronal death. Seizure-induced activation of forkhead transcription factors drive Bim overexpression, which quenches Bcl-w, an endogenous molecular brake on cell death. In turn, mice deficient in the Bcl-w gene exhibit a lowered threshold for injury following seizures, despite reactive upregulation of protective genes. Our central hypothesis is: Bim and Bcl-w regulate the majority of neuronal death after brief seizures.
The specific aims of this project are: 1. Characterize the expression and interactions of cell death regulators Bcl-w and Bim following brief seizures and in long-term epilepsy. 2. Investigate the effects of manipulating Bcl-w expression on seizure-induced damage and epileptogenesis. 3. Demonstrate the in vivo functional significance of Bcl-w and Bim by examining seizure-induced neuronal damage in mice deficient in each gene. 4. Determine the consequence of Bim and Bcl-w gene deletions on the generation of an epileptic phenotype. These studies will identify potent regulatory sites in the molecular pathways by which neurons die following .brief, electrographically defined seizures, thereby offering novel, focused neuroprotective targets beyond anticonvulsants for treating at-risk epilepsy patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS047622-01A2
Application #
6988568
Study Section
Clinical Neuroscience and Disease Study Section (CND)
Program Officer
Stewart, Randall R
Project Start
2005-07-01
Project End
2009-06-30
Budget Start
2005-07-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$358,438
Indirect Cost
Name
Emanuel Hospital and Health Center
Department
Type
DUNS #
050973098
City
Portland
State
OR
Country
United States
Zip Code
97232
Thompson, Simon J; Ashley, Michelle D; Stöhr, Sabine et al. (2011) Suppression of TNF receptor-1 signaling in an in vitro model of epileptic tolerance. Int J Physiol Pathophysiol Pharmacol 3:120-32
Engel, T; Hatazaki, S; Tanaka, K et al. (2010) Deletion of Puma protects hippocampal neurons in a model of severe status epilepticus. Neuroscience 168:443-50
Murphy, B M; Engel, T; Paucard, A et al. (2010) Contrasting patterns of Bim induction and neuroprotection in Bim-deficient mice between hippocampus and neocortex after status epilepticus. Cell Death Differ 17:459-68
Boison, Detlev (2008) Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol 8:2-7
Boison, Detlev (2008) The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84:249-62
Li, Tianfu; Ren, Gaoying; Lusardi, Theresa et al. (2008) Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice. J Clin Invest 118:571-82
Murphy, Brona; Dunleavy, Mark; Shinoda, Sachiko et al. (2007) Bcl-w protects hippocampus during experimental status epilepticus. Am J Pathol 171:1258-68
Li, Tianfu; Steinbeck, Julius A; Lusardi, Theresa et al. (2007) Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants. Brain 130:1276-88
Ren, Gaoying; Li, Tianfu; Lan, Jiang Quan et al. (2007) Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol 208:26-37
Boison, Detlev (2007) Adenosine as a modulator of brain activity. Drug News Perspect 20:607-11

Showing the most recent 10 out of 14 publications